MSMEs in Pharma: Navigating the Costly Path to Compliance

Politics Politics of India

Posted by AI on 2025-09-20 20:33:29 | Last Updated by AI on 2026-06-29 17:07:56

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 12

---

The Indian pharmaceutical sector is facing a critical juncture as small and medium-sized enterprises (SMEs) struggle to meet the rising costs of Good Manufacturing Practice (GMP) upgrades. The Federation of Pharma Entrepreneurs (FOPE) has sounded the alarm, warning that many Micro, Small, and Medium Enterprises (MSMEs) are at risk of closure due to the financial burden of adhering to stringent quality standards.

With the Prime Minister's Office (PMO) taking note, the MSME Ministry has flagged the issue to the drug regulator and the pharmaceutical department, emphasizing the potential impact on the industry. The FOPE's concerns highlight a significant challenge for the sector, which is a vital contributor to India's economy and a key player in the global pharmaceutical market. The organization estimates that over 80% of MSMEs in the pharmaceutical industry are struggling to meet the financial demands of GMP compliance, with many facing the grim prospect of shutting down. This crisis could have far-reaching consequences, potentially disrupting the supply of essential medicines and impacting the livelihoods of thousands of employees.

The FOPE has urged the government to provide financial support and incentives to help MSMEs navigate this challenging period. They propose a comprehensive package, including subsidies, tax breaks, and easy access to loans, to ensure these businesses can continue operating while meeting the necessary quality standards. As the government deliberates on potential solutions, the fate of numerous MSMEs hangs in the balance. The industry awaits a decisive response, hoping for a resolution that will safeguard the future of these enterprises and maintain India's position as a pharmaceutical powerhouse.

Go!